Abstract
Retinitis pigmentosa (RP), a heterogenous group of inherited retinal disorder causes slow progressive vision loss with no effective treatments available. Mutations in the rhodopsin gene (RHO), account for ∼25% cases of autosomal dominant RP (adRP). In this study, we describe the disease characteristics of the first ever reported mono-allelic copy number variation (CNV) in RHO as a novel cause of adRP. We (1) show advanced retinal degeneration in a male patient (60-70 year old) harboring four transcriptionally active intact copies of rhodopsin, (2) recapitulated the clinical phenotypes using retinal organoids, and (3) assessed the utilization of a small molecule, Photoregulin3 (PR3), as a clinically viable strategy to target and modify disease progression in RP patients associated with RHO-CNV. Patient retinal organoids showed photoreceptors dysgenesis, with rod photoreceptors displaying stunted outer segments with occasional elongated cilia-like projections (microscopy); increased RHO mRNA expression (qRT-PCR and bulk RNA-sequencing); and elevated levels and mislocalization of rhodopsin protein (RHO) within the cell body of rod photoreceptors (western blotting and immunohistochemistry) over the extended (300-days) culture time period when compared against control organoids. Lastly, we utilized PR3 to target NR2E3, an upstream regulator of RHO, to alter RHO expression and observed a partial rescue of RHO protein localization from the cell body to the inner/outer segments of rod photoreceptors in patient organoids. These results provide a proof-of-principle for personalized medicine and suggest that RHO expression requires precise control. Taken together, this study supports the clinical data indicating that adRP due to RHO-CNV develops due protein overexpression overloading the photoreceptor post-translational modification machinery.
Competing Interest Statement
Commercial relationships disclosures: Sangeetha Kandoi - None Cassandra Martinez - None Kevin Xu Chen - None Miika Mehine - None L Vinod K. Reddy - None Brian Mansfield - None Jacque L. Duncan - None Deepak A. Lamba - None
Funding Statement
The research presented here is supported by NEI R01 EY032197 (DAL), U24 EY029891 (DAL and JLD), UCSF Vision Core NIH/NEI P30 EY002162, CIRM DISC0-14449 (D.A.L), All May See Foundation post-doctoral fellowship (SK), and an unrestricted grant from Research to Prevent Blindness, New York, NY
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board (IRB) of the University of California, San Francisco gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding information: NEI R01 EY032197 and CIRM DISC0-14449 (D.A.L), U24 EY029891 (D.A.L and J.L.D), Foundation Fighting Blindness (D.A.L), All May See Foundation and Bright Focus Foundation Post-doctoral fellowship (S.K), UCSF Vision Core NIH/NEI P30 EY002162, and an unrestricted grant from Research to Prevent Blindness, New York, NY
Commercial relationships disclosures:
Sangeetha Kandoi - None
Cassandra Martinez - None
Kevin Xu Chen - None
Miika Mehine – None
L Vinod K. Reddy - None
Brian C. Mansfield - None
Jacque L. Duncan - None
Deepak A. Lamba - None
The revision is updated to match the one submitted to Elife for review. The revision has some new data based on reviewer comments.
Data Availability
All data produced in the present study will be available upon reasonable request to the authors.
